MSAA Hosting 8th Webinar on COVID-19 and MS 4.2 (19)
The Multiple Sclerosis Association of America (MSAA) is hosting a webinar in which experts will discuss the COVID-19 pandemic and its impact on multiple sclerosis (MS).
The webinar, “What You Need to Know About COVID-19 and MS: Program 8,” will take place at 8 p.m. EST on Jan. 25. It is the eighth installment of the MSAA’s ongoing webinar series about COVID-19 in people with MS.
This program will feature Barry Hendin, MD, the chief medical officer at the MSAA, alongside Carrie Hersh, DO, chair of the MSAA’s healthcare advisory council.
The doctors will present the latest findings on COVID-19, and also discuss current recommendations for MS care and overall health management. The webinar will feature an expanded question-and-answer session to address areas of concern. Additional information, as well as registration for the webinar, is available here.
MSC-NPs are seen as a possible way of treating people with progressive MS, who have few effective disease-modifying treatments available. They are essentially stem cells collected from a patient’s bone marrow that are expanded and matured to produce factors involved in modulating the immune response and in nervous tissue growth and survival.
An open-label Phase 1 trial (NCT01933802) investigated this stem cell treatment in 20 adults with stable primary (four PPMS patients) or secondary progressive MS (16 SPMS patients) and significant disability.
All received a total of three injections of MSC-NPs, given directly into the spinal canal three months apart. They were then evaluated at three and six months, and again at two years, after the final treatment to determine its long-term safety and tolerability, and for signs of potential effectiveness.
Click here to subscribe to the Multiple Sclerosis News Today Newsletter! 4.7 (23)
Adults with mild to moderate multiple sclerosis (MS) are being urged to participate in a new clinical trial STEP for MS that will assess the impact of two different exercise programs on patients’ mobility, walking abilities, and quality of life.
Funded by the Patient-Centered Outcomes Research Institute (PCORI), the STEP for MS trial expects to enroll around 400 MS patients, ages 18–65, who have difficulties walking and do not exercise regularly.
STEP for MS is recruiting participants at eight sites across seven U.S. states. More information can be found here.